Age of patients included and excluded by various eligibility criteria
| Variables . | MER cohort . | LEO cohort . | ||||
|---|---|---|---|---|---|---|
| n . | Age . | P2 . | n . | Age . | P2 . | |
| Age, y | ||||||
| 18-60 | 336 | 50.0 (8.7) | **** | 299 | 51.0 (8.5) | **** |
| >60 | 279 | 68.0 (7.0) | 284 | 69.0 (7.0) | ||
| 18-75 | 556 | 58.0 (11.5) | **** | 518 | 58.0 (11.4) | **** |
| >75 | 59 | 80 (4.2) | 65 | 80.0 (3.9) | ||
| Stage | ||||||
| III-IV | 501 | 59.0 (13.7) | 471 | 60.0 (13.3) | ||
| II | 105 | 60.0 (11.7) | 82 | 60.5 (13.3) | ||
| Renal function (creatinine) | ||||||
| <1.5 mg/dL | 487 | 59.0 (13.1) | *** | 459 | 60.0 (13.2) | ** |
| ≥1.5 mg/dL | 24 | 70.0 (13.6) | 26 | 68.0 (14.1) | ||
| <2 mg/dL | 508 | 60.0 (13.2) | 478 | 60.0 (13.2) | ** | |
| ≥2 mg/dL | 3 | 72.0 (22.5) | 7 | 74.0 (11.3) | ||
| Performance status | ||||||
| 0-1 | 581 | 59.0 (13.2) | 515 | 59.0 (13.0) | *** | |
| >1 | 31 | 60.0 (14.1) | 68 | 64.5 (12.7) | ||
| 0-2 | 605 | 59.0 (13.3) | 552 | 60.0 (13.2) | ||
| >2 | 7 | 66.0 (12.7) | 31 | 62.0 (11.9) | ||
| Prior malignancy | ||||||
| No previous malignancy | 557 | 58.0 (13.2) | **** | 526 | 59.0 (13.1) | **** |
| Any previous malignancy | 58 | 66.0 (10.9) | 57 | 68.0 (11.1) | ||
| No previous malignancy w/exceptions* | 575 | 59.0 (13.3) | *** | 546 | 60.0 (13.1) | **** |
| Any exception* | 36 | 66.5 (10.2) | 37 | 68.0 (11.8) | ||
| Hepatic function (total bilirubin) | ||||||
| <1.5 mg/dL | 495 | 60.0 (13.3) | 462 | 60.0 (13.3) | ||
| ≥1.5 mg/dL | 12 | 54.0 (11.2) | 6 | 62.5 (6.5) | ||
| <2 mg/dL | 504 | 60.0 (13.2) | 465 | 60.0 (13.3) | ||
| ≥2 mg/dL | 3 | 59.0 (19.2) | 3 | 61.0 (5.5) | ||
| Self-reported serious health conditions | ||||||
| None | 519 | 58.0 (13.4) | **** | 404 | 59.0 (13.3) | ** |
| Any serious health conditions | 96 | 66.0 (10.2) | 179 | 63.0 (12.5) | ||
| Hemoglobin | ||||||
| ≥9 g/dL | 544 | 60.0 (13.1) | 495 | 60.0 (13.3) | ||
| <9 g/dL | 13 | 61.0 (15.6) | 9 | 63.0 (10.0) | ||
| ≥8 g/dL | 550 | 60.0 (13.1) | not applicable | |||
| <8 g/dL | 7 | 49.0 (14.2) | not applicable | |||
| WBC | ||||||
| ≥3000/μL | 547 | 60.0 (13.1) | 495 | 60.0 (13.3) | ||
| <3000/μL | 9 | 61.0 (15.1) | 7 | 64.0 (9.5) | ||
| ≥4000/μL | 524 | 60.0 (13.2) | 474 | 60.0 (13.4) | ||
| <4000/μL | 32 | 55.5 (10.9) | 28 | 61.5 (9.5) | ||
| Platelet | ||||||
| ≥75 000/μL | 544 | 60.0 (13.1) | 495 | 60.0 (13.2) | * | |
| <75 000/μL | 11 | 60.0 (15.0) | 6 | 66.0 (9.4) | ||
| ≥150 000/μL | 489 | 60.0 (13.0) | 434 | 60.0 (12.9) | ||
| <150 000/μL | 66 | 59.5 (13.8) | 67 | 63.0 (14.8) | ||
| Variables . | MER cohort . | LEO cohort . | ||||
|---|---|---|---|---|---|---|
| n . | Age . | P2 . | n . | Age . | P2 . | |
| Age, y | ||||||
| 18-60 | 336 | 50.0 (8.7) | **** | 299 | 51.0 (8.5) | **** |
| >60 | 279 | 68.0 (7.0) | 284 | 69.0 (7.0) | ||
| 18-75 | 556 | 58.0 (11.5) | **** | 518 | 58.0 (11.4) | **** |
| >75 | 59 | 80 (4.2) | 65 | 80.0 (3.9) | ||
| Stage | ||||||
| III-IV | 501 | 59.0 (13.7) | 471 | 60.0 (13.3) | ||
| II | 105 | 60.0 (11.7) | 82 | 60.5 (13.3) | ||
| Renal function (creatinine) | ||||||
| <1.5 mg/dL | 487 | 59.0 (13.1) | *** | 459 | 60.0 (13.2) | ** |
| ≥1.5 mg/dL | 24 | 70.0 (13.6) | 26 | 68.0 (14.1) | ||
| <2 mg/dL | 508 | 60.0 (13.2) | 478 | 60.0 (13.2) | ** | |
| ≥2 mg/dL | 3 | 72.0 (22.5) | 7 | 74.0 (11.3) | ||
| Performance status | ||||||
| 0-1 | 581 | 59.0 (13.2) | 515 | 59.0 (13.0) | *** | |
| >1 | 31 | 60.0 (14.1) | 68 | 64.5 (12.7) | ||
| 0-2 | 605 | 59.0 (13.3) | 552 | 60.0 (13.2) | ||
| >2 | 7 | 66.0 (12.7) | 31 | 62.0 (11.9) | ||
| Prior malignancy | ||||||
| No previous malignancy | 557 | 58.0 (13.2) | **** | 526 | 59.0 (13.1) | **** |
| Any previous malignancy | 58 | 66.0 (10.9) | 57 | 68.0 (11.1) | ||
| No previous malignancy w/exceptions* | 575 | 59.0 (13.3) | *** | 546 | 60.0 (13.1) | **** |
| Any exception* | 36 | 66.5 (10.2) | 37 | 68.0 (11.8) | ||
| Hepatic function (total bilirubin) | ||||||
| <1.5 mg/dL | 495 | 60.0 (13.3) | 462 | 60.0 (13.3) | ||
| ≥1.5 mg/dL | 12 | 54.0 (11.2) | 6 | 62.5 (6.5) | ||
| <2 mg/dL | 504 | 60.0 (13.2) | 465 | 60.0 (13.3) | ||
| ≥2 mg/dL | 3 | 59.0 (19.2) | 3 | 61.0 (5.5) | ||
| Self-reported serious health conditions | ||||||
| None | 519 | 58.0 (13.4) | **** | 404 | 59.0 (13.3) | ** |
| Any serious health conditions | 96 | 66.0 (10.2) | 179 | 63.0 (12.5) | ||
| Hemoglobin | ||||||
| ≥9 g/dL | 544 | 60.0 (13.1) | 495 | 60.0 (13.3) | ||
| <9 g/dL | 13 | 61.0 (15.6) | 9 | 63.0 (10.0) | ||
| ≥8 g/dL | 550 | 60.0 (13.1) | not applicable | |||
| <8 g/dL | 7 | 49.0 (14.2) | not applicable | |||
| WBC | ||||||
| ≥3000/μL | 547 | 60.0 (13.1) | 495 | 60.0 (13.3) | ||
| <3000/μL | 9 | 61.0 (15.1) | 7 | 64.0 (9.5) | ||
| ≥4000/μL | 524 | 60.0 (13.2) | 474 | 60.0 (13.4) | ||
| <4000/μL | 32 | 55.5 (10.9) | 28 | 61.5 (9.5) | ||
| Platelet | ||||||
| ≥75 000/μL | 544 | 60.0 (13.1) | 495 | 60.0 (13.2) | * | |
| <75 000/μL | 11 | 60.0 (15.0) | 6 | 66.0 (9.4) | ||
| ≥150 000/μL | 489 | 60.0 (13.0) | 434 | 60.0 (12.9) | ||
| <150 000/μL | 66 | 59.5 (13.8) | 67 | 63.0 (14.8) | ||
Age is represented by median (SD). P values via 2-sample t tests for continuous variables and χ2 tests for categorical variables: *<.05, **<.01, ***<.001, ****<00001.
Exceptions consist of nonmelanoma skin cancer, breast cancer, cervical cancer in situ, and uterine cancer in situ.